Manufacturing News of Note—Pact Pharma snags Kite's Tim Moore; Catalent, Minerva hook up


> South San Francisco-based Pact Pharma has enticed Tim Moore from Gilead's Kite Pharma to serve as Pact's president and chief technical officer as it develops TCR-T cell therapies for the eradication of solid tumors. Release 

> Catalent and clinical-stage biotech Minerva Neurosciences have struck a deal for the CDMO to manufacture and package the finished dose form of roluperidone (MIN-101), Minerva’s investigational compound for the treatment of symptoms of schizophrenia. Release 

> Cellectis, a Swiss biotech working on immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), has reached an agreement for Lonza to handle clinical manufacturing. Release

> Novasep has launched Senefill, a unit dedicated to fill-and-finish aseptic commercial operations. It is in Seneffe, Belgium. Release

> Nanoform will conduct an evaluation of its nanoparticle technology across a range of AstraZeneca’s pharmaceutical products. Release

> CapsCanada, which makes vegetarian K-CAPS, is moving its headquarters to a facility in Dania Beach, Florida. Release 



Suggested Articles

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.

The FDA knocked a California compounding pharmacy facility for a suite of sanitary concerns, including the presence of ants in the plant.

Merck Animal Health will plow $100 million into its DeSoto, Kansas, plant to scale up production of animal vaccines.